Flow cytometric crossmatching in primary renal transplant recipients with a negative anti-human globulin enhanced cytotoxicity crossmatch

Journal of the American Society of Nephrology

Volumn 12, Issue 12, 2001, Pages 2807-2814

  Karpinski, M ^a   Rush, D ^a   Jeffery, J ^a   Exner, M ^a   Regele, H ^a   Dancea, S ^a   Pochinco, D ^a   Birk, P ^a   Nickerson, P ^a  

^a CANADIAN BLOOD SERVICES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN; IMMUNOGLOBULIN ANTIBODY;

ADULT; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY TEST; FEMALE; FLOW CYTOMETRY; GRAFT REJECTION; HISTOPATHOLOGY; HUMAN; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECIPIENT; RECURRENT DISEASE; RISK FACTOR; SCREENING; T LYMPHOCYTE;

EID: 0035195594     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Flow cytometry analysis: A high technology crossmatch technique facilitating transplantation
2. Sensitization and sensitivity: Defining the unsensitized patient
3. Long-term graft survival is improved in cadaveric renal retransplantation by flow cytometric crossmatching
4. Flow cytometry cross-matching as a predictor of acute rejection in sensitized recipients of cadaveric renal transplants
5. The flow cytometric crossmatch and early renal transplant loss
6. Flow cytometry-detected IgG is not a contraindication to renal transplantation
7. Flow cytometry crossmatching and primary cadaver kidney graft outcome: Relevance of T and B cell targets, historic sera and autologous controls
8. The relevance of a more sensitive crossmatch assay in renal transplantation
9. The significance of a positive flow cytometry crossmatch test in primary kidney transplantation
10. No advantage of flow cytometry crossmatch over complement-dependent cytotoxicity in immunologically well-documented renal allograft recipients
11. T-cell flowcytometry cross-match: Influence in renal transplantation
12. Variations of the lymphocytotoxicity test: An evaluation of sensitivity and specificity
13. Capillary deposition of C 4d complement fragment and early renal allograft loss
14. Deposition of C 4d in peritubular capillaries is a marker of acute humoral renal allograft rejection
15. C4d deposits in renal allografts are associated with inferior graft outcome
16. Simultaneous HLA class I and class II antibodies screening with flow cytometry
17. Intrarenal distribution of endothelial antigens recognized by antibodies from renal allograft recipients
18. Vascular endothelial alloantigens in renal transplantation
19. Antibodies eluted from acutely rejected renal allografts bind to and activate human endothelial cells
20. IgG antibodies against an HLA antigen are associated with activated cytotoxic T cells against this antigen, IgM are not
21. Pregnancy can induce priming of cytotoxic T lymphocytes specific for paternal HLA antigens that is associated with antibody formation
22. Risk factors for chronic rejection in renal allograft recipients
23. Immunologic factors: The major risk for decreased long-term renal allograft survival
24. Beneficial effects of treatment of early subclinical rejection: A randomized study
25. Association between a positive flow cytometry crossmatch and the development of chronic rejection in primary renal transplantation
26. Successful renal transplantation in patients with T-cell reactivity to donor
27. Transplantation with a past positive crossmatch and cyclosporine immunosuppression: A 5-year experience
28. The effect of historical crossmatches and sensitization of renal allograft survival
29. Renal transplantation to sensitized patients: Decreased graft survival probability associated with a positive historical crossmatch
30. The relevance of donor T cell-directed immunoglobulin G in historic sera in the age of flow cytometry
31. Renal transplantation despite a positive antiglobulin crossmatch with and without prophylactic OKT 3
32. Cadaveric renal transplantation with a quadruple immunosuppression in patients with a positive antiglobulin crossmatch
33. Removal of anti-HLA antibodies by extracorporeal immunoadsorption to enable renal transplantation
34. Immunoadsorption of anti-HLA antibodies for highly sensitized patients awaiting renal transplantation
35. Beneficial effects of double-filtration plasmapheresis on living related donor renal transplantation in presensitized recipients
36. Prevention of hyperacute rejection by removal of antibodies to HLA immediately before renal transplantation
37. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients
38. A high panel-reactive antibody rescue protocol for cross-match-positive live donor kidney transplants
39. Suppression of the humoral immune response by mycophenolate mofetil
40. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ
41. Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg)
42. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action
43. Hyperacute and acute kidney graft rejection due to antibodies against B cells
44. Identification of patients at risk for inferior renal allograft outcome by a strongly positive B cell flow cytometry crossmatch